News

The US Patent and Trademark Office has issued a patent to PolyMedix, relating its angiogenesis inhibitors. The patent number 7,553,876, entitled ‘Polycationic Compounds and Uses Thereof,’ relates to

Advanced Therapeutics (ADVTX) has announced that Fibrinoplate-S has shown efficacy in reducing the bleeding in animals exposed to extreme doses of radiation. Reportedly in preclinical trials, Fibrinoplate-S reduced

AdviTech has completed its initial funding round by securing commitments of $3.4 million, including $2.5 million from the Texas Emerging Technology Fund (ETF). Wesley Krueger, chairman and chief

Baxter and Halozyme have completed patient enrollment in the phase III pivotal study of Gammagard Liquid with rHuPH20 (recombinant human hyaluronidase enzyme). It is to be used for

Nature & Health is conducting a voluntary nationwide recall of the five supplement products sold under the following names: LibieXtreme, Y-4ever, Libimax X Liquid, Powermania Liquid and Capsule,

Data Monitoring Committees (DMCs), after predefined interim analyses, recommended that Paion should proceed with their phase IIa study, as well as phase Ib of CNS 7065 for anesthetic/sedative.

Watson Laboratories (Watson), a subsidiary of Watson, has filed an Abbreviated New Drug Application (ANDA) with the FDA. The company is seeking approval to market its trospium chloride

Abbott has announced strong financial results for the second quarter ended June 30, 2009. Diluted earnings per share, excluding specified items, were $0.89, at the high end of

EnVivo has completed phase Ib/IIa trial in Alzheimer’s disease patients with its nicotinic alpha-7 agonist EVP-6124. Subjects receiving EVP-6124 experienced improvement in cognition and EVP-6124 showed good tolerability